In a published phase three BouNDless trial, the investigational Parkinson treatment ND0612 demonstrates efficacy and safety.

Published Date: 21 Mar 2024

In adults with Parkinson disease, a 24-hour subcutaneous infusion of ND0612 was more effective at reducing off time and increasing on time without causing bothersome dyskinesia than oral immediate-release levodopa–carbidopa.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot